The Role of the Molecular Subtypes in the Prognosis of Breast Cancer Patients
BACKGROUND: Understanding the biology of the tumor, by dividing it into molecular subtypes, has made it possible to individualize the therapeutic approach in high-risk patients.
AIM: We aimed to determine the importance of established molecular subtypes in the prognosis and the importance of disease-free and overall survival (OS) in patients with non-metastatic breast cancer.
MATERIALS AND METHODS: We analyzed 94 patients with non-metastatic breast cancer for the period 2010â€“2018. The median follow-up time was 60 months. The mean age in the study group was 60.03 years (SD Â± 10.52). According to the characteristics of the studied indicators, we divided the group into Luminal A (n-59 [62.7%]), Luminal B/HER2 (âˆ’) (n-2 [2.1%]), Luminal B/HER2 (+) (n-8 [8.5%]), HER2 overexpressing (n-3 [3.2%]), and triple-negative subtype (n-22 [23.5%]). In all patients in the study group, we analyzed the 5-year overall survival (OS) and disease-free survival (DFS) and referred it to molecular subtypes, lymphatic status, HER-2 status, the presence or absence of endocrine therapy for the follow-up period, tumor differentiation, and type of surgery.
RESULTS: We observed the 5-year OS in 92% of patients identified as Luminal A; at 50% of Luminal B/HER2 (âˆ’) neg.; in 62.5% with Luminal B/HER2 (+), in 67% with HER2-overexpressing carcinoma; and in 66.7% of patients with triple-negative subtype. The total cancer-associated mortality rate in the analyzed period reached 15.9% (n = 15). Patients with mastectomy (p = 0.019, p = 0.027), positive axilla with more than 4 lymph node (LN) (p = 0.000; p = 0.000), and Luminal B/HER-2 (+) tumors (p = 0.004; p = 0.003) were the independent prognostic factors for worse DFS and OS in our study group. Histological differentiation and HER-2 expression were in unsatisfactory correlation (p = 0.077; p = 0.044 and p = 0.081; p = 0.055, respectively).
CONCLUSION: Molecular subtypes are essential in the prognosis of breast cancer and maybe a criterion for an individualized therapeutic approach.
Plum Analytics Artifact Widget Block
DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52-62. https://doi. org/10.3322/caac.21203 PMid:24114568
Early Breast Cancer Trialistsâ€™ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365(9472):1687-717. https:// doi.org/10.1016/s0140-6736(05)66544-0 PMid:15894097
Perou CM, SÃ¸rlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52. https://doi.org/10.1038/35021093 PMid:10963602
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61- 70. https://doi.org/10.1038/nature11412 PMid:23000897
Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov. 2013;3(1):27-34. PMid:23319768
Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5(1):5-23. PMid:21147047
Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: A retrospective of the last decade. J Pathol. 2010;220(2):263-80. https://doi.org/10.1002/ path.2648 PMid:19927298
Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-7. https://doi. org/10.1200/jco.2008.18.1370 PMid:19204204
Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360(8):790-800. https://doi. org/10.1056/nejmra0801289 PMid:19228622
Goldhirsch A, Wood WC, Coates AS, Gelber RD, ThÃ¼rlimann B, Senn HJ, et al. Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22(8):1736-47. https://doi.org/10.1093/ annonc/mdr304 PMid:21709140
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart- Gebhart M, ThÃ¼rlimann B, et al. Personalizing the treatment of women with early breast cancer: Highlights of the St gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24(9):2206-23. https://doi. org/10.1016/j.breast.2003.09.007 PMid:23917950
Hennigs A, Riedel F, Gondos A, Sinn P, Schirmacher P, MarmÃ© F, et al. Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. BMC Cancer. 2016;16(1):734. https://doi.org/10.1186/s12885-016-2766-3 PMid:27634735
Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, et al. Global burden of cancer in 2008: A systematic analysis of disability-adjusted life-years in 12 world regions. Lancet. 2012;380(9856):1840-50. https://doi. org/10.1016/s0140-6736(12)60919-2 PMid:23079588
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 2010;127(12):2893-917. https://doi. org/10.1002/ijc.25516 PMid:21351269
Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10, 159 cases from 12 studies. PLoS Med. 2010;7(5):e1000279. https://doi.org/10.1371/journal. pmed.1000279 PMid:20520800
Williams C, Lin CY. Oestrogen receptors in breast cancer: Basic mechanisms and clinical implications. Ecancermedicalscience. 2013;7:370. PMid:24222786
Eroles P, Bosch A, PÃ©rez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012;38(6):698-707. https://doi. org/10.1016/j.ctrv.2011.11.005 PMid:22178455
Hashmi AA, Aijaz S, Khan SM, Mahboob R, Irfan M, Zafar NI, et al. Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients. World J Surg Oncol. 2018;16(1):1. https://doi.org/10.1186/s12957-017-1299-9 PMid:29291744
Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol. 2010;21(4):717-22. https://doi.org/10.1093/ annonc/mdp388 PMid:19825882
de Ronde J, Wessels L, Wesseling J. Molecular subtyping of breast cancer: Ready to use? Lancet Oncol. 2010;11(4):306-7. https://doi.org/10.1016/s1470-2045(10)70036-x PMid:20359657
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies-improving the management of early breast cancer: St gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26(8):1533-46. https://doi.org/10.1016/j. breast.2003.09.007
Vallejos CS, GÃ³mez HL, Cruz WR, Pinto JA, Dyer RR, Velarde R, et al. Breast cancer classification according to immunohistochemistry markers: Subtypes and association with clinicopathologic variables in a peruvian hospital database. Clin Breast Cancer. 2010;10(4):294-300. https://doi.org/10.3816/ cbc.2010.n.038 PMid:20705562
Denkert C, von Minckwitz G. Reply to Ki67 in breast cancer: A useful prognostic marker! Ann Oncol. 2014;25(2):542-3. https://doi.org/10.1093/annonc/mdt564 PMid:24431345
Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736- 50. https://doi.org/10.1093/jnci/djp082 PMid:19436038
Dowsett M, Nielsen TO, Aâ€™Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: Recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst. 2011;103(22):1656-64. https://doi.org/10.1093/jnci/djr393 PMid:21960707
Luporsi E, AndrÃ© F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, et al. Ki-67: Level of evidence and methodological considerations for its role in the clinical management of breast cancer: Analytical and critical review. Breast Cancer Res Treat. 2012;132(3):895-915. https://doi. org/10.1007/s10549-011-1837-z PMid:22048814
Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, et al. An international Ki67 reproducibility study. J Natl Cancer Inst. 2013;105(24):1897-906. PMid:24203987
Copyright (c) 2020 Stoyan Nikolov, Emil Enchev, Georgi Minkov, Evgeni Dimitrov, Koni Ivanova, Maya Gulubova, Tatyana Vlaykova, Yovcho Yovtchev (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All rights reserved.